

REFERENCE

- Aghaii S.S., Kamaly A., Esfahani M. 2012, Meta-Analysis of Individual and Environmental Factors that Influence People's Addiction Tendencies. *Int J High Risk Behav Addict*, **1**(3): 92-9.
- Aguilar G.L., López A.M., Aceituno C.B., Ávila J.A., Guerrero J.A., and Quesada R.A. 2016, DNA Source Selection for Downstream Applications Based on DNA Quality Indicators Analysis. *Biopreservation and Biobanking*, **14**(4): 264-270.
- Ahmed, M., Ul Haq, I., Faisal, M., Waseem, D., & Taqi, M. M. 2018, Implication of OPRM1 A118G Polymorphism in Opioids Addicts in Pakistan: In vitro and In silico Analysis. *Journal of molecular neuroscience*, **65**(4), 472–479
- APA. 2013, *Substance-Related and Addictive Disorders. The Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition. American Psychiatric Association.
- Arias A., Feinn R., Kranzler H.R. 2006, Association of an Asn40asp (A118G) Polymorphism in the Mu-Opioid Receptor Gene with Substance Dependence: A Meta-Analysis. *Drug Alcohol Depend.*, **83**: 262–268.
- Badel A., Greaney B. 2013, *Exploring the Link between Drug Use and Job Status in the U.S.* The Regional Economist. St. Louis Fed.
- Barber R.D., Harmer D.W., Coleman R.A., and Clark B.J. 2005, GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. *Physiol Genomics*, **21**: 389–395.
- Birren, B., E Lai. 1993, *Pulsed field gel electrophoresis: a practical guide*. San Diego: Academic Press, Inc.
- BNN (National Narcotic Agency). 2017, *Executive Summary Survei Penyalahgunaan Narkoba Di Indonesia Tahun 2017*. Puslitdatin BNN.
- Chou W.Y., Wang C.H., Liu P.H., Liu C.C., Tseng C.C., Jawan B. 2006, Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. *Anesthesiology*, **105**: 334–7.
- Ciccarone, D. 2011, Stimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy. *Prim Care*, **38**(1): 41–58.
- Crist, R.C. dan Berrettini, W.H. 2014, Pharmacogenetics of *OPRM1*. *Pharmacology, Biochemistry, and Behavior*, **123**: 25–33.

- Crist, R.C., Doyle, G.A., Nelson, E.C., Degenhardt, L., Martin, N.G., Montgomery, G.W., et al. 2018, A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. *The Pharmacogenomics Journal*, **18**: 173–179.
- Das K., Fernando M.R., Basiaga S., Wigginton S., Williams T. 2014, Effects of a novel cell stabilizing reagent on DNA amplification by PCR as compared to traditional stabilizing reagents. *Acta Histochemica*, **116**: 55–60.
- De Gregori M., Garbin G., De Gregori S., Minella C.E., Bugada D., Lisa A., et al. 2013, Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. *Eur J Clin Pharmacol*, **69**: 1651–8.
- Dlugos, A.M., Hamidovic, A., Hodgkinson, C., Shen, P.H., Goldman, D., Palmer, A.A., et al. 2011, *OPRM1* gene variants modulate amphetamine-induced euphoria in humans. *Genes, Brain and Behavior*, **10**: 199–209.
- Fothergill K.E., Ensminger M.E., Green K.M., Crum R.M., Robertson J., & Juon H.S. 2008, The impact of early school behavior and educational achievement on adult drug use disorders: a prospective study. *Drug and alcohol dependence*, **92**(1-3): 191–199.
- Fukuda K., Hayashida M., Ide S., Saita N., Kokita Y., Kasai S., et al. 2009, Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. *Pain*, **147**: 194–201.
- Garibyan, L. and Avashia, N. 2013, Research Techniques Made Simple: Polymerase Chain Reaction (PCR). *J Invest Dermatol*, **133**(3): e6.
- Hancock, D.B., Levy, J.L., Gaddis, N.C., Glasheen, C., Saccone, N.L., Page, G.P., et al. 2015, Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in *OPRM1*. *Biological Psychiatry*, **78**: 474–484.
- Handoyo, D., Ari, R. 2000, Prinsip Umum dan Pelaksanaan Polymerase Chain Reaction (PCR). *Unitas*, **9**(1):17-29
- Hart, A.B., de Wit, H., and Palmer, A.A. 2012, Genetic Factors Modulating the Response to Stimulant Drugs in Humans, in: Cryan, J.F. dan Reif, A. (Editor), *Behavioral Neurogenetics*. Springer Berlin Heidelberg, Berlin, Heidelberg, **12**:537–577.
- Hasin, D.S., Saha, T.D., Kerridge, B.T., et al. 2015, Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. *JAMA Psychiatry*, **72**(12):1235-1242.

- Henker R.A., Lewis A., Dai F., Lariviere W.R., Meng L., Gruen G.S., et al. 2013, The associations between OPRM 1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. *Biol Res Nurs*, 15: 309–17.
- Hofer T., Ray N., Wegmann D., Excoffier L. 2009, Large Allele Frequency Differences between Human Continental Groups are more likely to have Occurred by Drift During range Expansions than by Selection. *Annals of Human Genetics*, **73**: 95-108.
- Hwang, I.C., Park, J.-Y., Myung, S.-K., Ahn, H.Y., Fukuda, K., and Liao, Q. 2014, *OPRM1* A118G Gene Variant and Postoperative Opioid Requirement: A Systematic Review and Meta-analysis. *Anesthesiology*, **121**: 825–834.
- Koechl B., Ungera A., and Fischer G. 2012, Age-related aspects of addiction. *Gerontology*, **58**(6): 540–544.
- Kumar D., Chakraborty J., Das S. 2012, Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, **36**: 225–230.
- Kumar, P., Pokotylyuk, I., Kulshrestha, S., and Loewy, Z. 2018, Clinical Relevance of μ -Opioid Receptor A118G Polymorphism in Demographically Variant Populations. *EC Pharmacology and Toxicology*, **6**(4): 228-236.
- Madras, B.K. 2018, The President’s Commission on Combating Drug Addiction and the Opioid Crisis: Origins and Recommendations. *Clinical Pharmacology and Therapeutics*.
- Mattei J., Parnel L.D., Lai C., Bailo B., Adiconis X., Shen J., et al. 2009, Disparities in allele frequencies and population differentiation for 101 disease-associated single nucleotide polymorphisms between Puerto Ricans and non-Hispanic whites. *BMC Genetics*, **10**: 45.
- Mehmedic, Z., Chandra, S., Slade, D., et al. 2010, Potency trends of Δ^9 -THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. *J Forensic Sci*, **55**(5):1209-1217.
- Miko I., LeJeune L. 2009, eds. *Essentials of Genetics*. Cambridge, MA: NPG Education.
- Morgan, C.J.A., Page, E., Schaefer, C., et al. 2013, Cerebrospinal fluid anandamide levels, cannabis use, and psychotic-like symptoms. *Br J Psychiatry J Ment Sci*, **202**(5):381-382.
- Müller, C.P., Homberg, J.R. 2015, The role of serotonin in drug use and addiction. *Behav Brain Res*. **277**:146-92.

- Musa, N. 2017, *Genetics and Inter-individual Variability of Methadone Metabolism*. Doctor of Philosophy, Universiti Sains Malaysia.
- Nagaya, D., Ramanathan, S., Ravichandran, M., et al. 2012, A118G mu opioid receptor polymorphism among drug addicts in Malaysia. *J Integr Neurosci*, **11**(1):117-122.
- National Institute on Drug Abuse. 2015, *Drugs of Abuse: Opioids*. Bethesda, MD: National Institute on Drug Abuse. Accessed on 2018, October 25. <http://www.drugabuse.gov/drugs-abuse/opioids>
- National Institute on Drug Abuse. 2018, *Commonly Abused Drugs and Withdrawal Symptoms*. Accessed on 2018, November 10. <http://www.drugabuse.gov/researchers>
- National Institute on Drug Abuse. 2019, *Methamphetamine*. Accessed on 2019, June 15. <https://www.drugabuse.gov/publications/drugfacts/methamphetamine>
- NCBI. 2019, *GAPDH glyceraldehyde-3-phosphate dehydrogenase [Homo sapiens (human)]*. National Center for Biotechnology Information, U.S. National Library of Medicine. Accessed on 2019, June 16. <https://www.ncbi.nlm.nih.gov/gene/2597>
- NIH. 2019, *OPRM1 gene, opioid receptor mu 1*. U.S. Department of Health & Human Services. Accessed on 2018, November 10. <https://ghr.nlm.nih.gov/gene/OPRM1>
- Nikolov, M.A., Beltcheva, O., Galabova, A. 2011, 'No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian casecontrol sample. *Drug Alcohol Depend.*, **117**(1): 62–65.
- Olson K.M., Lei W., Keresztes A., LaVigne J., and Streichera J.M. 2017, Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain. *Yale J Biol Med*, **90**(1): 97–110.
- Pelt-Verkuil, E. van, Belkum, A. van, and Hays, J.P. 2008, *Principles and Technical Aspects of PCR Amplification*. Springer Science & Business Media.
- Pérez-Mañá, C., Castells, X., Torrens, M., Capellà, D., dan Farre, M. 2013, Efficacy of psychostimulant drugs for amphetamine abuse or dependence. *Cochrane Database of Systematic Reviews*
- Qiagen. 2010, *QIAamp DNA Mini and Blood Mini Handbook*, Third Ed. Qiagen Sample & Assay Technologies.

- Ralston, S.H., Penman, I.D., Strachan, M.W.J., and Hobson, R. 2018, *Davidson's Principles and Practice of Medicine E-Book*. Elsevier Health Sciences.
- Rodriguez S, Gaunt T, et al. 2009, Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies. *American Journal of Epidemiology*. Advance Access published on January 6, 2009.
- Scheier, L.W. 2010, *Handbook of Drug Use Etiology: Theory, Methods, and Empirical Findings*. American Psychological Association.
- Schwantes-An, T.-H., Zhang, J., Chen, L.-S., Hartz, S.M., Culverhouse, R.C., Chen, X., et al. 2016, Association of the *OPRM1* variant rs1799971 (A118G) with non-specific liability to substance dependence in a collaborative de novo meta-analysis of European-ancestry cohorts. *Behavior Genetics*, **46**: 151–169.
- Singh, A.K. 2019, Alcohol Interaction with Cocaine, Methamphetamine, Opioids, Nicotine, Cannabis, and γ -Hydroxybutyric Acid. *Biomedicines*, **7**(16).
- Smith, T.W., Hout M., and Marsden P.V. 2013, *General Social Survey, 1972-2012* [Cumulative File]. ICPSR34802-v1. Storrs, CT: Roper Center for Public Opinion Research, University of Connecticut /Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributors].
- Tien L.T. and Ho I.K. 2011, Involvement of μ -Opioid Receptor in Methamphetamine-Induced Behavioral Sensitization. *Curr Neuroparmacol*, **9**(1): 215–218.
- U.S. Department of Health and Human Services (HHS), 2016. *Office of the Surgeon General, Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health*. Washington, DC: HHS
- Valentino R.J., Volkow N.D. 2018, Untangling the complexity of opioid receptor function. *Neuropsychopharmacology*, **43**: 2514–2520.
- Van den Oever M.C., Spijker S., Smit A.B. 2012, *The Synaptic Pathology of Drug Addiction*. In: Kreutz M., Sala C. (eds) *Synaptic Plasticity. Advances in Experimental Medicine and Biology*, **970**. Springer, Vienna
- Weighardt F., Biamonti G., and Riva S. 1993, A Simple Procedure for Enhancing PCR Specificity. *Genome Res.*, **3**: 77-80.
- Windle, M., Gray, J.C., Lei, K.M., et al. 2018, Age sensitive associations of adolescent substance use with amygdala, ventral striatum, and frontal volumes in young adulthood. *Drug and Alcohol Dependence*, **186**: 94-101.
- Woodcock E.A., Lundah L.H., Burmeister M., and Greenwald M.K., 2015, Functional Mu Opioid Receptor Polymorphism (OPRM1 A118G)

Associated With Heroin Use Outcomes in Caucasian Males: A Pilot Study.
Am J Addict, **24**(4): 329–335.

World Health Organization. 2003, *The ICD-10 Classification of Mental and Behavioral Disorders: Clinical descriptions and diagnostic guidelines*. Accessed on 2019, June 10. https://www.who.int/substance_abuse/terminology/ICD10ClinicalDiagnosis.pdf

World Health Organization. 2014, *International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)-2014-WHO Version for;2014*. Accessed on 2019, June 27. <https://icd.who.int/browse10/2014/en#>

Xu, J., Wang, T., Su, Z., et al. 2018, Opioid Exposure is Associated with Aberrant DNA Methylation of *OPRM1* Promoter Region in a Chinese Han Population. *Biochem Genet*, **56**:451–458

Zahari Z, and Ismail R. 2013, Impact of Opioid Receptor, Mu 1 (OPRM1) Polymorphisms on Pain Sensitivity and Clinical Response to Opioid Analgesic Therapy. *Current Pharmacogenomics and Personalized Medicine*, **11**:59-75.

Zahari, Z, Ibrahim M.A., Musa N., Tan S.C., Mohamad N., Ismail R. 2018, Sleep quality and OPRM1 polymorphisms: a cross-sectional study among opioid-naïve individuals. *Braz. J. Pharm. Sci.* **54**(1):e17217

Zwisler S.T., Enggaard T.P., Mikkelsen S., Verstuyft C., Becquemont L., Sindrup S.H., Brosen K. 2012, Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. *J Clin Pharmacol*, **52**: 234–42.